Head and Neck Cancer — Expanded Access Programs
Overview
Right2Hope maintains a directory of 68 expanded access programs, clinical trials, and compassionate use pathways listed for Head and Neck Cancer. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with head and neck cancer programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 17 programs are currently active or recruiting, with the remaining 51 in other lifecycle stages. Sponsors actively running programs in this area include Memorial Sloan Kettering Cancer Center, Trisha Wise-Draper, University of Chicago, University of California, San Diego, BioAtla, Inc., and others.
By recruiting status
Snapshot of where every Head and Neck Cancer program currently sits in its lifecycle.
- Active / Recruiting17
- Inactive51
Top sponsors
Organisations running the most Head and Neck Cancer programs in the directory.
- Memorial Sloan Kettering Cancer Center5 programs
- Trisha Wise-Draper4 programs
- University of Chicago4 programs
- University of California, San Diego3 programs
- BioAtla, Inc.2 programs
- Dana-Farber Cancer Institute2 programs
- M.D. Anderson Cancer Center2 programs
- Providence Health & Services2 programs
- Radiation Therapy Oncology Group2 programs
- Rakuten Medical, Inc.2 programs
Head and Neck Cancer programs (68)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Study on Xevinapant with Cisplatin and Radiation Therapy After Surgery for Head and Neck Cancer — Memorial Sloan Kettering Cancer Center
- Study on ASP-1929 Photoimmunotherapy for Patients with Recurrent Head and Neck Cancer — Rakuten Medical, Inc.
- Study on Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) for Patients with Incurable Head and Neck Cancer — Washington University School of Medicine
- Study on Evorpacept (ALX148) with Pembrolizumab and Chemotherapy for Advanced Head and Neck Cancer — ALX Oncology Inc.
- Expanded Access Program for SL-28 in Treating Advanced Solid Tumors — Second Life Therapeutics
- Study Comparing Two Types of Neck Radiation Therapy for Head and Neck Cancer — University of Texas Southwestern Medical Center
- Study on Lead-212 PSV359 Therapy for Patients with Solid Tumors — Perspective Therapeutics
- Study on Using Chemotherapy and Immunotherapy Before Surgery for Head and Neck Cancer — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Study on Immunotherapy and Radiation Before Surgery for Head and Neck Cancer — Providence Health & Services
- Study on NT219 Combined with Standard Biologic Therapy for Recurrent or Metastatic Head and Neck Cancer — University of Colorado, Denver
- Phase 2 Study on Personalized Radiation Therapy for Head and Neck Cancer — H. Lee Moffitt Cancer Center and Research Institute
- Phase II Study of Adding Pembrolizumab to Standard Treatment for Head and Neck Cancer After Surgery — Trisha Wise-Draper
- Study on Preserving Swallowing Ability in Oral Cavity Cancer Patients: Comparing Radiation Treatments — Lawson Health Research Institute
- Study on Radiation Therapy With or Without Chemotherapy for High-Risk Salivary Gland Tumors Removed by Surgery — Radiation Therapy Oncology Group
- Radiation Therapy With or Without Cetuximab for Patients After Surgery for Advanced Head and Neck Cancer — Radiation Therapy Oncology Group
- Study on Retifanlimab with INCAGN02385 and INCAGN02390 for First-Line Treatment of PD-L1-Positive Head and Neck Cancer — Incyte Biosciences International Sàrl
- Study on Nivolumab With or Without Ipilimumab for Oral Cavity Squamous Cell Carcinoma — Dana-Farber Cancer Institute
- "QUAD SHOT" Radiotherapy with Pembrolizumab for Patients with Recurrent Head and Neck Cancer — University of Oklahoma
- Study on KVA12123 Treatment Alone and with Pembrolizumab for Advanced Solid Tumors (VISTA-101) — Kineta Inc.
- Phase 2 Study of BA3021 for Treating Recurrent or Metastatic Head and Neck Cancer — BioAtla, Inc.
- Phase 2a Study on Using Pegsitacianine for Detecting Cancer in Patients with Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY) — University of Texas Southwestern Medical Center
- Study Comparing Pembrolizumab and Placebo for Preventing Recurrence in High-Risk Head and Neck Cancer — University of Chicago
- Study on Reducing Radiation and Chemotherapy in People with Head and Neck Cancer — Memorial Sloan Kettering Cancer Center
- Study on HER3-DXd for Advanced or Metastatic Solid Tumors — Daiichi Sankyo
- Study on Pembrolizumab and Chemotherapy for Head and Neck Cancer — University of Chicago
- Study on SNS-101 Alone and with Cemiplimab for Advanced Solid Tumors — Sensei Biotherapeutics, Inc.
- Study on Using Nivolumab After Surgery in Head and Neck Cancer Patients Previously Treated with Radiation — Trisha Wise-Draper
- Study on ASP-1929 Photoimmunotherapy for Recurrent Head and Neck Cancer in Patients Who Have Tried at Least Two Treatments — Rakuten Medical, Inc.
- Study on Alternating Treatment Plans for Advanced Lung or Head and Neck Cancer — Rutgers, The State University of New Jersey
- Study on Using CAR-T Cells Targeting CSPG4 for Treating Relapsed or Hard-to-Treat Head and Neck Cancer — UNC Lineberger Comprehensive Cancer Center
- Study on CAB-ROR2-ADC for Treating Advanced Breast, Head & Neck, Lung Cancer, and Melanoma — BioAtla, Inc.
- Study on Cisplatin and Radiation Therapy for Head and Neck Cancer and Its Link to Oxidative Stress — Susanne Arnold
- Study on MDX2001 for Patients with Advanced Solid Tumors — ModeX Therapeutics, An OPKO Health Company
- Study on Durvalumab and Cetuximab for Previously Treated Recurrent or Metastatic Head and Neck Cancer — Trisha Wise-Draper
- Early Access Program for HER2/HER3 Bispecific Antibody MCLA-128 for Patients with Advanced NRG1-Fusion Positive Solid Tumors — Merus N.V.
- Expanded Access to Ulixertinib (BVD-523) in Patients with Advanced MAPK Pathway-Altered Malignancies — xCures
- Imaging With a PET Agent for Detection of Cancers of the Head and Neck — Memorial Sloan Kettering Cancer Center
- Study on LYT-200 Alone and in Combination with Chemotherapy or Tislelizumab for Advanced or Metastatic Solid Tumors — PureTech
- Study on Immunoradiotherapy Before Surgery for Head and Neck Cancer — Providence Health & Services
- Study on OSI-774, Cisplatin, and Taxotere for Treating Head and Neck Cancer — M.D. Anderson Cancer Center
- Study on PD-L1 t-haNK, N-803, and Cetuximab for Advanced Head and Neck Cancer — Glenn J. Hanna
- Study on PDT Induction Therapy for Head and Neck Cancer — Massachusetts General Hospital
- Study on Pembrolizumab and Cetuximab for Treating Recurrent or Metastatic Head and Neck Cancer — University of California, San Diego
- Study on Combining PD-1 Inhibitor with Radiation Therapy Before Surgery for Recurrent Head and Neck Cancer — University of Cincinnati
- Phase II Study of Panitumumab-IRDye800 for Head and Neck Cancer — University of Alabama at Birmingham
- Preoperative Immunotherapy for Patients with Head and Neck Squamous Cell Carcinoma — Alain Algazi
- Study on Pembrolizumab and Chemotherapy Before and After Surgery for Treatable, Returning Head and Neck Cancer — Dana-Farber Cancer Institute
- Study on Proton Therapy for Recurrent Head and Neck Cancer — Memorial Sloan Kettering Cancer Center
- Study on RAPA-201 Therapy for Solid Tumors — Rapa Therapeutics LLC
- Study on Response-Adaptive Treatment for Untreated HPV-Negative Head and Neck Cancer — University of Chicago
- Study on the Safety and Effectiveness of APG-157 for Head and Neck Cancer — Aveta Biomics, Inc.
- Study on Selective Additional Therapy for HPV-related Throat Cancer Based on Blood Test Results — University of Maryland, Baltimore
- Study on BT5528 for Patients with Advanced Solid Tumors Linked to EphA2 Expression — BicycleTx Limited
- Study on Niraparib and Dostarlimab for Treating Recurrent or Metastatic Head and Neck Cancer — Trisha Wise-Draper
- Study for Participants Continuing from Pfizer-Sponsored Palbociclib Studies — Pfizer
- Study on ALE.C04 for Patients with Head and Neck Cancer — Alentis Therapeutics AG
- Study of BDC-3042 Alone and with Cemiplimab in Patients with Advanced Cancers — Bolt Biotherapeutics, Inc.
- Study on Chemotherapy with Cisplatin/Carboplatin and Docetaxel, with or without Erlotinib, for Treating Head and Neck Cancers That Can Be Surgically Removed — M.D. Anderson Cancer Center
- Study on EOS-448 with Standard and Experimental Treatments for Advanced Solid Tumors — iTeos Belgium SA
- Study on Pembrolizumab and Valemetostat for Treating Certain Head and Neck Cancers — National Cancer Institute (NCI)
- Study on INBRX-106 Alone and with Pembrolizumab (Keytruda®) for Advanced Solid Tumors — Inhibrx Biosciences, Inc
- Study Comparing Proton and Photon Beam Radiotherapy for Head and Neck Cancer — Memorial Sloan Kettering Cancer Center
- Study on Tadalafil and Pembrolizumab for Recurrent or Metastatic Head and Neck Cancer — University of California, San Diego
- Study on PC14586 for Patients with Advanced Solid Tumors with a TP53 Y220C Mutation (PYNNACLE) — PMV Pharmaceuticals, Inc
- Study on TheraT® Vectors (Vaccines) and Chemotherapy for Treating HPV16 Head and Neck Cancers — University of Chicago
- Study on Tislelizumab with Other Investigational Drugs for Head and Neck Cancer — BeiGene
- Study on Ibrutinib Combined with Nivolumab or Cetuximab for Treating Recurrent or Metastatic Head and Neck Cancer — University of California, San Diego
- Study on IPI-549 for Patients with Locally Advanced Head and Neck Cancer — Ezra Cohen
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Head and Neck Cancer to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.